innate pharma s.a. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system. innate pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells. the company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs. innate pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of natural killer cell biology. this innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including astrazeneca, bristol-myers squibb, novo nordisk a/s and sanofi. innate pharma
Company profile
Ticker
IPHA, IPHYF
Exchange
Website
CEO
Mondher Mahjoubi
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Innate Pharma, SA
SEC CIK
IPHA stock data
Latest filings (excl ownership)
6-K
Innate Pharma Announces Advancement Of Sanofi-Developed Nk Cell Engager Sar443579 / Iph6101 Progressing To Phase 2 For Blood Cancer Patients
15 Apr 24
6-K
Current report (foreign)
15 Apr 24
6-K
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
10 Apr 24
20-F
2023 FY
Annual report (foreign)
4 Apr 24
6-K
Summary of Consolidated Financial Statements and Notes
21 Mar 24
6-K
Innate Pharma reports Full Year 2023 Financial Results and Business Update
21 Mar 24
6-K
Innate Pharma Announces Its Participation To Upcoming Investor Conference
19 Mar 24
6-K
Innate Pharma Announces Conference Call And Webcast For Full Year 2023 Financial Results
14 Mar 24
6-K
Current report (foreign)
6 Mar 24
6-K
Current report (foreign)
6 Mar 24
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
9.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 820.34 mm |
Total shares | 7.51 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bpifrance Participations | 7.19 mm | $15.81 mm |
Optiver Holding B.V. | 190.22 k | $481.25 mm |
Millennium Management | 46.97 k | $118.84 mm |
MS Morgan Stanley | 44.95 k | $113.73 mm |
Exchange Traded Concepts | 35.00 k | $88.55 mm |
Steward Partners Investment Advisory | 500.00 | $1.27 mm |
BCS Barclays | 412.00 | $1.00 k |
Rhumbline Advisers | 205.00 | $518.00 k |
UBS UBS Group AG - Registered Shares | 146.00 | $369.00 k |
Proequities | 0.00 | $0.00 |
News
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
11 Apr 24
Innate Pharma Presents Preclinical Efficacy Of Its Pre-IND Drug Candidate IPH45, A Novel Nectin-4 Antibody Drug Conjugate At AACR 2024
10 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
3 Apr 24
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
22 Mar 24
Earnings Scheduled For March 21, 2024
21 Mar 24
Press releases
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
15 Apr 24
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
15 Apr 24
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
10 Apr 24
Innate Pharma Announces Its Participation in Upcoming Investor Conference
9 Apr 24
Innate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F
5 Apr 24